Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

AFT PHARMACEUTICALS LIMITED

ARBN

609 017 969

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued | Fully paid ordinary shares or to be issued
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 473, 181 (New Shares) issued pursuant to a share purchase plan.
- 3 Principal terms *securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for if +convertible payment; securities, the conversion price and dates conversion)

The New Shares rank pari passu with existing ordinary shares

⁺ See chapter 19 for defined terms.

4 the ⁺securities rank equally in all respects from the ⁺issue date with an existing +class of quoted +securities?

Yes. From the issue date, the New Shares will rank equally in all respects with the existing fully paid ordinary shares in AFP.

If the additional *securities do not rank equally, please state:

- the date from which they
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Issue price or consideration | A\$2.11 (NZ\$2.25) per New Share

6 Purpose of the issue (If issued as consideration the acquisition clearly identify assets, those assets)

5

AFP is raising new capital to provide additional balance sheet capacity to enable AFP to pursue its current and planned R&D programme, as well as taking advantage of the codeine rescheduling decision in its key Australian market, and expanding its distribution channels internationally.

6a Is the entity an *eligible entity that has obtained security holder approva1 under rule 7.1A?

> If Yes, complete sections 6b 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If ⁺ securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements	N/A

⁺ See chapter 19 for defined terms.

7 *Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

16 June	2017

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

+Class
Ordinary

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and *class of all
*securities not quoted on ASX
(including the *securities in
section 2 if applicable)

Number	+Class
3, 330, 000	Redeemable
	Preference Shares
849, 000	Options to acquire
	Ordinary Fully
	Paid Shares

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The shares rank pari passu with existing ordinary shares and will have the same dividend rights as other ordinary shares on issue.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

0.0	N. C.	N / A
20	Names of any underwriters	N/A
0.4		[/.
21	Amount of any underwriting fee or commission	N/A
	or commission	
22	Names of any brokers to the	N/A
	issue	
23	Fee or commission payable to	N/A
	the broker to the issue	
24	Amount of any handling fee	N/A
	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	on bondii or security norders	
25	If the issue is contingent on	N/A
	security holders' approval, the date of the meeting	
	the date of the meeting	
26	Date entitlement and	N/A
	acceptance form and offer documents will be sent to	
	persons entitled	
27	If the entity has issued	N/A
	options, and the terms entitle option holders to participate	
	on exercise, the date on which	
	notices will be sent to option holders	
	HOTAGE 2	
28	Date rights trading will begin	N/A
	(if applicable)	
29	Date rights trading will end	N/A
<i>∆</i> ∂	(if applicable)	14/14
30	How do security holders sell	N/A
	their entitlements in full	
	through a broker?	

⁺ See chapter 19 for defined terms.

31 How do security holders sell part of their entitlements through a broker and accept for the balance?

N/A			

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A
	3 - Quotation of secu	urities I are applying for quotation of securities
34	Type of *securities (tick one)	
(a)	*Securities described in	Part 1
(b)		the end of the escrowed period, partly paid securities that become re securities when restriction ends, securities issued on expiry or es
	es that have ticked box 3 onal securities forming a ne	
Tick inform	to indicate you are providing mation or documents	g the
35	1 1	equity securities, the names of the 20 largest l +securities, and the number and percentage of eld by those holders
36		requity securities, a distribution schedule of ies setting out the number of holders in the
37	A copy of any trust deed	for the additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do		
	 the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do 		
	not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for	N/A	
41	Reason for request for quotation now	IV/ A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	
	crause out		

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

⁺ See chapter 19 for defined terms.

Quotation agreement

- †Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Sign Date:15 June 2017 (Company secretary)	here:
Print name: Malcolm Tubby	

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	N/A	
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	N/A	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid †ordinary securities cancelled during that 12 month period	N/A	
"A"	N/A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	N/A
Step 3: Calculate "C", the amount 7.1 that has already been used	t of placement capacity under rul
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	N/A
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	N/A
Step 4: Subtract "C" from ["A" x 'placement capacity under rule 7.1	
"A" x 0.15 Note: number must be same as shown in Step 2	N/A
Subtract "C"	N/A
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	N/A
	[Note: this is the remaining placement

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	N/A	

Appendix 3B Page 16 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.